Prescribing Trends of Osteoporosis Medications, Adherence and Persistence with Denosumab versus Alendronate: A Real-World Retrospective Study in China.
- 1Department of Pharmacy, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China.
- 2Department of Orthopedic Surgery, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China.
- 3Department of Human Resources, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China.
Abstract
Introduction
Osteoporosis, a common metabolic bone disease with high fracture risk and heavy global burden, requires long-term medication adherence and persistence for fracture prevention, yet both remain suboptimal. Prescribing trends, adherence, and persistence data for denosumab and alendronate remain limited, especially in Chinese populations.Methods
This retrospective cohort study used hospital data. Patients aged ≥50 who newly initiated denosumab or alendronate in 2023-2025 were screened; 2025 initiators were excluded for insufficient 1-year follow-up. New users had no prior prescription of either drug since 2009. The proportion of days covered (PDC) was assessed, with good adherence defined as ≥80%. Persistence was time from initiation to discontinuation, with >60-day gap after coverage end defining discontinuation for both drugs. Propensity score matching (PSM) balanced baseline characteristics. Multivariable logistic regression and Kaplan-Meier survival analysis compared adherence and persistence.Results
A shift in prescribing from oral to injectable formulations, with alendronate decreasing by 44% and denosumab increasing by 94% in 2023-2025. Denosumab demonstrated greater persistence and adherence than alendronate. The 1-year persistence rate was 46.28% (95% CI: 41.88%-50.80%) for denosumab vs 2.89% (95% CI: 1.60%-4.79%) for alendronate, with a 90.80% lower risk [HR: 0.092 (95% CI: 0.077-0.110), p < 0.001]. PDC was 0.530 (IQR: 0.493-0.975), adherence rate 46.90% (227/484) for denosumab vs 0.077 (IQR: 0.077-0.153), 2.48% (12/484) for alendronate; adherence was 41.29-fold higher with denosumab (95% CI: 22.41-76.07, p < 0.001). Multivariate analysis showed hypertension and fracture history with better adherence and persistence; inpatient status was associated with poorer persistence and adherence; and female sex with poorer persistence (all p < 0.05).Conclusions
A shift from oral to injectable formulations was observed. Denosumab was associated with higher persistence and adherence than alendronate. Hypertension and fracture history were associated with better persistence and adherence, whereas inpatient status was associated with poorer persistence and adherence. Female sex was associated with poorer persistence without affecting adherence.
Related
- 24-month real-world persistence and compliance of denosumab versus alendronate among postmenopausal women with osteoporosis in Australia, Taiwan, South Korea, Hong Kong, and Singapore
- Effects of different anti-osteoporosis medications on re-fracture risk, bone mineral density, and functional recovery following hip fragility fracture surgery: a systematic review and network meta-analysis
- Patterns and appropriateness of antipsychotic prescribing in community-dwelling older adults: a retrospective study
- Clinical profiles, referral patterns and low vision aid prescribing across four rehabilitation centres in Ghana: protocol for a multicentre retrospective record review
- Medication Use Patterns and Exposure to High-Risk Medications Among Pregnant Women Seeking Counseling from a Teratology Information Service: A Nine-Year Retrospective Study
BibTeX
@article{chen2026prescribing,
title = {{Prescribing Trends of Osteoporosis Medications, Adherence and Persistence with Denosumab versus Alendronate: A Real-World Retrospective Study in China.}},
author = {Jun Chen and Yuliang Huang and Puqing Liu and Lei Fan},
journal = {Patient preference and adherence},
year = {2026},
month = oct,
doi = {10.2147/ppa.s642741},
url = {https://europepmc.org/article/MED/42899211},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Prescribing Trends of Osteoporosis Medications, Adherence and Persistence with Denosumab versus Alendronate: A Real-World Retrospective Study in China.
AU - Jun Chen
AU - Yuliang Huang
AU - Puqing Liu
AU - Lei Fan
PY - 2026
DA - 2026/10/15
JO - Patient preference and adherence
DO - 10.2147/ppa.s642741
UR - https://europepmc.org/article/MED/42899211
AB - Introduction Osteoporosis, a common metabolic bone disease with high fracture risk and heavy global burden, requires long-term medication adherence and persistence for fracture prevention, yet both remain suboptimal. Prescribing trends, adherence, and persistence data for denosumab and alendronate remain limited, especially in Chinese populations.Methods This retrospective cohort study used hospital data. Patients aged ≥50 who newly initiated denosumab or alendronate in 2023-2025 were screened; 2025 initiators were excluded for insufficient 1-year follow-up. New users had no prior prescription of either drug since 2009. The proportion of days covered (PDC) was assessed, with good adherence defined as ≥80%. Persistence was time from initiation to discontinuation, with >60-day gap after coverage end defining discontinuation for both drugs. Propensity score matching (PSM) balanced baseline characteristics. Multivariable logistic regression and Kaplan-Meier survival analysis compared adherence and persistence.Results A shift in prescribing from oral to injectable formulations, with alendronate decreasing by 44% and denosumab increasing by 94% in 2023-2025. Denosumab demonstrated greater persistence and adherence than alendronate. The 1-year persistence rate was 46.28% (95% CI: 41.88%-50.80%) for denosumab vs 2.89% (95% CI: 1.60%-4.79%) for alendronate, with a 90.80% lower risk [HR: 0.092 (95% CI: 0.077-0.110), p < 0.001]. PDC was 0.530 (IQR: 0.493-0.975), adherence rate 46.90% (227/484) for denosumab vs 0.077 (IQR: 0.077-0.153), 2.48% (12/484) for alendronate; adherence was 41.29-fold higher with denosumab (95% CI: 22.41-76.07, p < 0.001). Multivariate analysis showed hypertension and fracture history with better adherence and persistence; inpatient status was associated with poorer persistence and adherence; and female sex with poorer persistence (all p < 0.05).Conclusions A shift from oral to injectable formulations was observed. Denosumab was associated with higher persistence and adherence than alendronate. Hypertension and fracture history were associated with better persistence and adherence, whereas inpatient status was associated with poorer persistence and adherence. Female sex was associated with poorer persistence without affecting adherence.
SN - 1177-889X
ER -